Register to use all the features of this website, including selecting clinical areas of interest and “favourite” articles, taking part in quizzes and much more.
Hint: If you are a General Practitioner your username may be your MCNZ#
About us | FAQ | Contact us | Terms of use
Interactive quizzes are based on material found in Best Practice Journal and Best Tests. Initially, quizzes are posted out with journals and GPs are invited to submit their answers for CME credits.
Register or Log in to take part in quizzes.
Login to my bpac.
Don't have an account? Register to use all the features of this website, including selecting clinical areas of interest, taking part in quizzes and much more.
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists have been recommended... View Article
Prescribers in New Zealand are highly reliant on cilazapril as their “go-to” ACE inhibitor, but this prescribing is out of step... View Article
Patients currently prescribed cilazapril + hydrochlorothiazide combination tablets will need to transition to a different combination... View Article
Biological medicines are an important advancement in the pharmaceutical treatment of patients with inflammatory and immunological... View Article
View Article
Changes in funded brands of antiepileptic medicines can lead to concern from patients or caregivers that the medicine they are... View Article
Patients taking oral flecainide or amiodarone need to know that the suppliers of these medicines have changed and that they may... View Article
Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor available fully subsidised from 1 October, 2018. DPP-4 inhibitors have... View Article
From 1 June, 2018, aripiprazole can be prescribed without Special Authority approval, making access easier for patients who require... View Article
From 1 May, 2018, pregabalin will be available to prescribe, fully subsidised. From 1 June, 2018, prescribing restrictions will... View Article
Methylnaltrexone injections are now subsidised for the treatment of opioid-induced constipation for patients in palliative care.... View Article
Intravenous ferric carboxymaltose is now a potential option for treating patients with iron deficiency anaemia in the community.... View Article
From 1 May, 2017, 4% dimethicone lotion can be prescribed fully subsidised for the treatment of head lice, which adds another... View Article
The human papillomavirus virus (HPV) vaccine reduces the incidence of HPV-related diseases, including genital warts and cervical... View Article
This article has been archived. If you would like access to the original article please contact: editor@bpac.org.nz View Article
Ticagrelor (Brilinta) is a new oral antiplatelet medicine, which has been available, fully subsidised, with Special Authority,... View Article
An approved medicine is a medicine which has been through a regulatory process in New Zealand and can be considered safe to prescribe,... View Article
From November 1, 2010 donepezil will be funded without Special Authority, on the Pharmaceutical Schedule. Donepezil and other... View Article
Nicotinic acid/laropiprant (Tredaptive) ▪ Fosamax Plus ▪ Direct-to-consumer genetic testing View Article
PHARMAC carefully considers whether brand changes for specific medicines are appropriate, taking into account clinical risks.... View Article
This article has been archived; for a copy of the original, please email editor@bpac.org.nz View Article
Visits the main points around changing to a generic drug from varoius viewpoints. View Article
Advice on counselling patients through a brand change. View Article